OBJECTIVE: The aim of this study was to evaluate the prevalence of cancer testis tumor-associated antigens MAGE-A and NY-ESO-1 in cervical cancer and correlate expression patterns with clinicopathologic parameters and prognosis. STUDY DESIGN: One hundred sixty-two cervical cancer samples from 109 patients who were treated with radical hysterectomy, neoadjuvant chemotherapy, or pelvic disease recurrence were analyzed by immunohistochemistry. RESULTS: MAGE-A was expressed by 32/94 (34%) and 7/15 (47%) previously untreated and recurrent tumors, respectively. NY-ESO-1 was expressed by 46/94 (49%) and 6/15 (40%) previously untreated and recurrent tumors, respectively. MAGE-A in early stage tumors was correlated to tumor size and lymph node metastases (P = .024 and P = .046, respectively) whereas NY-ESO-1 to tumor grading (P = .039). CONCLUSION: Cervical cancer frequently expresses cancer testis tumor-associated antigens. MAGE-A and NY-ESO-1 expression rates are not influenced by systemic therapies. Cancer testis tumor-associated antigens are correlated to common prognostic factors.
OBJECTIVE: The aim of this study was to evaluate the prevalence of cancer testis tumor-associated antigens MAGE-A and NY-ESO-1 in cervical cancer and correlate expression patterns with clinicopathologic parameters and prognosis. STUDY DESIGN: One hundred sixty-two cervical cancer samples from 109 patients who were treated with radical hysterectomy, neoadjuvant chemotherapy, or pelvic disease recurrence were analyzed by immunohistochemistry. RESULTS: MAGE-A was expressed by 32/94 (34%) and 7/15 (47%) previously untreated and recurrent tumors, respectively. NY-ESO-1 was expressed by 46/94 (49%) and 6/15 (40%) previously untreated and recurrent tumors, respectively. MAGE-A in early stage tumors was correlated to tumor size and lymph node metastases (P = .024 and P = .046, respectively) whereas NY-ESO-1 to tumor grading (P = .039). CONCLUSION: Cervical cancer frequently expresses cancer testis tumor-associated antigens. MAGE-A and NY-ESO-1 expression rates are not influenced by systemic therapies. Cancer testis tumor-associated antigens are correlated to common prognostic factors.
Authors: Shyamal D Weeraratne; Vladimir Amani; Adrianne Neiss; Natalia Teider; Deborah K Scott; Scott L Pomeroy; Yoon-Jae Cho Journal: Neuro Oncol Date: 2010-12-22 Impact factor: 12.300
Authors: Yu Zeng; Yanan He; Fan Yang; Steven M Mooney; Robert H Getzenberg; John Orban; Prakash Kulkarni Journal: J Biol Chem Date: 2011-02-25 Impact factor: 5.157
Authors: Takahito Suyama; Takumi Shiraishi; Yu Zeng; Wayne Yu; Nehal Parekh; Robert L Vessella; Jun Luo; Robert H Getzenberg; Prakash Kulkarni Journal: Prostate Date: 2010-12-01 Impact factor: 4.104
Authors: Anita Grigoriadis; Otavia L Caballero; Keith S Hoek; Leonard da Silva; Yao-Tseng Chen; Sandra J Shin; Achim A Jungbluth; Lance D Miller; David Clouston; Jonathan Cebon; Lloyd J Old; Sunil R Lakhani; Andrew J G Simpson; A Munro Neville Journal: Proc Natl Acad Sci U S A Date: 2009-07-27 Impact factor: 11.205